Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fuchun Granules is a Traditional Chinese Medicine (TCM) product developed by Jilin Province Beiyao Pharmaceutical Material Station, specifically indicated for the treatment of menopausal syndrome (perimenopausal syndrome). The formulation is designed to address symptoms such as hot flashes, sweating, dizziness, tinnitus, and emotional disturbances like irritability or insomnia. In the context of TCM theory, it functions by nourishing the kidney yin and clearing deficiency heat. The active herbal constituents, which typically include *Epimedium* and *Rehmannia*, contain bioactive small molecules like icariin that act as phytoestrogens. These compounds are thought to modulate estrogen receptor activity, providing a stabilizing effect on the hypothalamic-pituitary-ovarian axis to mitigate the physiological impacts of declining endogenous estrogen levels during menopause.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fuchun Granules.